About US
Contact us
-
FibroGen founder Neff dies suddenly as drug he championed racks up milestonesAfter founding FibroGen in 1993 and leading the company for 26years, chairman and CEO Thomas B. Neff passed away over the weekend unexpectedly. His death comes as FibroGen nears the critical U.S. and2019/8/26
-
Amgen, maker of Enbrel, to pick up Celgene's Otezla for $13.4B. Will FTC hit back?Looks like Amgen might not be buying Alexion Pharmaceuticals after all. Instead, it’s beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel. Amgen Monday said it willtake i2019/8/23
-
Does Novartis' delay in probing data manipulation claims spell trouble?Why did Novartis wait about two months before launching an internal probe into the alleged data manipulation surrounding gene therapy Zolgensma? That's what officials at the FDA want to know. After a2019/8/23
-
Should J&J owe billions for Oklahoma's opioid crisis? We'll find out MondayOpioiddrugmakersface thousands of lawsuits around the country, a mountain of them grouped in Cleveland’s federal court. But right now, it'sa Monday decision—in the first opioid case to make it to tri2019/8/22
-
Amgen-Alexion deal rumors resurface, to the delight of investors and analystsRumors that Amgen is looking to prop up its top and bottom lines by buying Alexion have been floating around for more than a year. Now, they’ve resurfaced, much to the delight of Wall Street analysts2019/8/22
-
Not so fast, Endo and Allergan: Ohio's AG is looking past your opioid dealsWith national opioid litigation heating up, Endo and Allergan saw an off-ramp and took it, agreeing to settle with two Ohio counties for a combined $16 million this week. But the state'sattorney gene2019/8/21
-
2-month HIV injection could be on its way, as ViiV touts new dual-drug winImagine HIV patients needed to take their antiretroviral therapies not every day, not even every month, but every two months. A GlaxoSmithKline two-drug injectable regimen that’s already under review2019/8/21
-
AstraZeneca and FibroGen's roxadustat, not yet filed in U.S., nabs 2nd anemia nod in ChinaFibroGen has not even filed its AstraZeneca-partnered oral anemia drug roxadustat forU.S. approval. But the collaborators have already scored theirsecond nod for the blockbuster hopeful in China. Las2019/8/20
-
Enough hubbub about HHS' Truvada patents, Gilead says. We're challenging them at the PTODrugmakershave often lambasted the U.S. Patent and Trademark Office’s (PTO's) interpartesreview system, but now Gilead Sciences is hoping to use it to its advantage. Thedrugmakeristaking onthe U.S. g2019/8/20
-
Dillon, who shaped NICE into an influential gatekeeper, ready to exit CEO postTwenty years after its founding, England’s National Institute for Health and Care Excellence (NICE) has established itself as perhaps the world’s preeminent drug cost watchdog. Now, the only leader i2019/8/19